Chapter 119 Appendage Tumors and Hamartomas of the Skin
Total Page:16
File Type:pdf, Size:1020Kb
11. Stambolic V et al: Negative regulation of PKB/Akt- Chapter 119 dependent cell survival by the tumor suppressor Appendage Tumors PTEN. Cell 95:29, 1998 12. Ponti G et al: Value of MLH1 and MSH2 mutations and Hamartomas of in the appearance of Muir-Torre syndrome phe- notype in HNPCC patients presenting sebaceous the Skin gland tumors or keratoacanthomas. J Invest Dermatol 126:2302-2307, 2006 Divya Srivastava & R. Stan Taylor 13. Thiboutot D: Regulation of human sebaceous glands. J Invest Dermatol 123:1-12, 2004 14. James WD, Berger TG, Elston DM: Andrews’ Dis- eases of the Skin: Clinical Dermatology. Philadel- phia, Elsevier Health Sciences, 2005 15. Troy JL, Ackerman AB. Sebaceoma. A distinctive benign neoplasm of adnexal epithelium differen- tiating toward sebaceous cells. Am J Dermatopa- REFERENCES thol 6:7-13, 1984 16. Jadassohn J. Bemerkuger zur histologieder sys- tematisirten naevi and ueber “Talgdrusen-navi”. 1. Requena L et al: Neoplasms with Apocrine Differ- Arch Derm Syphilol 33:355-394, 1895 entiation. Philadelphia, Lippincott-Raven, Ardor 17. Carlson JA et al: Epidermodysplasia verruciformis- Scribendi, 1997 associated and genital-mucosal high-risk human 2. Steffen C, Ackerman AB: Neoplasms with Se- papillomavirus DNA are prevalent in nevus seba- baceous Differentiation. Philadelphia, Lea and ceus of Jadassohn. J Am Acad Dermatol 59:279-94, Febiger, 1994 2008 3. Ackerman AB et al: Neoplasms with Follicular Dif- 18. Happle R, Konig A: Familial nevus sebaceus may ferentiation. New York, Ardor Scribendi, 2001 be explained by paradominant transmission. Br J Dermatol 141:377, 1999 4. Ahmed TS, Del Priore J, Seykora J: Tumors of the Epidermal Appendages in Lever’s Histopathology, 19. Xin H et al: The sebaceous nevus: A nevus 10th ed., edited by DE Elder, R Elenitsas, B John- with deletions of the PTCH gene. Cancer Res son, G Murphy, G Xu. Philadelphia, Lippincott, 59(8):1834-1836, 1999 Williams, and Wilkins, 2009 20. Jacqueti G, Requena L, Sanchex Yus E: Trichoblas- 5. Alsaad KO, Obaidat NA, Ghazarian D: Skin adnexal toma is the most common neoplasm developed neoplasms—Part 1: An approach to tumors of in nevus sebaceus of Jadassohn: A clinicopatho- the pilosebaceous unit. J Clin Pathol 60:129-144, logic study of a case series of 155 cases. Am J 2007 Dermatopathol 22:108-118, 2000 6. Obaidat NA, Alsaad KO, Ghazarian D: Skin adnexal 21. Eisen DB, Michael DJ: Sebaceous lesions and their neoplasms—Part 2: An approach to tumors of associated syndromes: Part I. J Am Acad Dermatol cutaneous sweat glands. J Clin Pathol 60:145-159, 61(4):549-560 2007 22. Mehregan AH, Pinkus H: Life history of organoid 7. Storm CA, Seykora JT: Cutaneous adnexal neo- nevi: Special reference to nevus sebaceous of plasms. Am J Clin Pathol 118(Suppl. 1):S33-S49, jadassohn. Arch Dermatol 91:574-588, 1965 2002 23. Cribier B, Scrivener Y, Grosshans E: Tumors arising 8. McCalmont TH: A call for logic in the classifica- in nevus sebaceous: A study of 596 cases. J Am tion of adnexal neoplasms. Am J Dermatopathol Acad Dermatol 42:63-68, 2000 18(2):111, 1996 24. Ball EAM, Hussain M, Moss ALH: Squamous cell 9. Biernat W et al: p53 mutations in sweat gland carcinoma and basal cell carcinoma arising in a carcinomas. Int J Cancer 76:317, 1998 nevus sebaceus of Jadassohn: Case report and literature review. Clin Exp Dermatol 30:259-260, 10. Aszterbaum M et al: Ultraviolet and ionizing 2005 radiation enhance the growth of BCCs and tricho- blastomas in patched heterozygous knockout 25. Wilson JE, Heyl T: Nevus sebaceus. Br J Dermatol mice. Nat Med 5:1285, 1999 82:99, 1970 696 Chapter 119: Appendage Tumors and Hamartomas of the Skin 26. Eisen DB, Michael DJ: Sebaceous lesions and their 43. Sawyer AR et al: Should extraocular sebaceous associated syndromes: Part II. J Am Acad Dermatol carcinoma be investigated using sentinel node 61(4):563-578, 2009 biopsy. Dermatol Surg 35(4):704-708, 2009 27. Ashinoff R: Linear nevus sebaceus of Jadassohn 44. Omura NE et al: Sebaceous carcinoma in children. treated with the carbon dioxide laser. Pediatr J Am Acad Dermatol 47(6):950-953, 2002 Dermatol 10:189-191, 1993 45. Dasgupta T, Wilson LD, Yu JB: A Retrospective 28. Kovich O, Hale EK: Nevus sebaceus. Dermatol review of 1349 cases of sebaceous carcinoma. Online J 11:16, 2005 Cancer 115(1):158-165, 2009 29. Dierickx CC et al: Photodynamic therapy for 46. Snow SN et al: Sebaceous carcinoma of the nevus sebaceus with topical delta-aminolevulinic eyelids treated by Mohs micrographic surgery: acid. Arch Dermatol 135:637-640, 1999 Report of nine cases with review of the literature. Dermatol Surg 28:623-631, 2002 30. Kumar P, Barton SP, Marks R: Tissue measure- ments in senile sebaceous gland hyperplasia. Br J 47. Bailet JW et al: Sebaceous carcinoma of the Dermatol 118:397-402, 1988 head and neck. Arch Otolaryngol Head Neck Surg 118(11):1245-1249 31. Salim A et al: Sebaceous hyperplasia and skin cancer in patients undergoing renal transplant. J 48. Harrington CR, Egbert BM, Swetter SM: Extraocu- Am Acad Dermatol 55:878-881, 2006 lar sebaceous carcinoma in a patient with Muir- Torre syndrome. Dermatol Surg 30:817-819, 2004 32. Boschnakow A et al: Ciclosporin A-induced seba- ceous gland hyperplasia. Br J Dermatol 149:198- 49. Reina RS, Parry E: Aggressive extraocular seba- 200, 2003 ceous carcinoma in a 52-year-old man. Dermatol Surg 32:1283-86, 2006 33. Richey DF: Aminolevulinic acid photodynamic therapy for sebaceous gland hyperplasia. Derma- 50. Muir EG, Bell AJY, Barlow KA: Multiple primary tol Clin 25:59-65, 2007 carcinomata of the colon, duodenum, and larynx associated with keratoacanthomata of the face. 34. Ma HJ, Zhao G, Wang YX: Sebaceous hyperplasia Br J Surg 54:191-195, 1967 of the scrotum in an adolescent boy. Pediatr Dermatol 24:340-342, 2007 51. Torre D: Multiple sebaceous tumors. Arch Derma- tol 98:549-551, 1968 35. Al-Daraji WI et al: Sebaceous hyperplasia of the vulva: A clinicopathological case report with a 52. Mangold E et al: A genotype-phenotype cor- review of the literature. J Clin Pathol 60:835-837, relation in HNPCC: A strong predominance of 2007 MSH2 mutations in 41 patients with Muir-Torre syndrome. J Med Genet 41:567-571, 2004 36. Woldow AB, Houk LD, Samie F: Juxtaclavicular beaded lines: A presentation of sebaceous hyper- 53. Hampel H et al: Cancer risk on hereditary nonpol- plasia. Dermatol Online J 15(4):14, 2009 yposis colorectal cancer syndrome: Later age of onset. Gastroenterology 129:415-421, 2005 37. Davis TT, Calilao G, Fretzin D: Sebaceous hyper- plasia overlying a dermatofibroma. Am J Derma- 54. Archer-Dubon C et al: Immunohistochemistry topathol 28:155-157, 2006 screening of sebaceous lesions for Muir Torre syndrome in a 26 year period in a Mexican popu- 38. Choi MJ, Kim JW, Koh BK: Solitary premature lation. Dermatol Online J 14(12):1, 2008 sebaceous hyperplasia associated with acneiform eruption. Acta Derm Venereol 84:483-484, 2004 55. Khashayar A, Khachemoune A: Hidrocystomas— A brief review. Med Gen Med 8(3):57, 2006 39. Zaballos P et al: Dermoscopy of sebaceous hyper- plasia. Arch Dermatol 141:808, 2005 56. Anzai S et al: Apocrine Hidrocystoma: A case report and analysis of 167 Japanese cases. Int J 40. Abbas O, Mahalingam M: Cutaneous sebaceous Dermatol 44:702-703, 2005 neoplasms as markers of Muir-Torre syndrome: A diagnostic algorithm. J Cutan Pathol 36:613-619, 57. Holder WR, Smith JD, Mocega EE: Giant apocrine 2009 hidrocystoma. Arch Dermatol 104:522-523, 1971 41. Lever WF: Sebaceous Adenoma. Arch Derm Syphi- 58. Alessi E, Gianotti R, Coggi: Multiple apocrine lol 57(1):102-111, 1948 hidrocystomas of the eyelids. Br J Dermatol 137:642-645, 1997 42. Rulon DB, Helwig EB: Cutaneous sebaceous neo- plasms. Cancer 33:82-102, 1974 59. Malliah U, Dickinson J: Multiple bilateral eyelid apocrine hidrocystomas and ectodermal dyspla- sia. Arch Opthalmol 119:1866, 2001 Copyright© McGraw-Hill Companies, Inc. All rights reserved. Chapter 119: Appendage Tumors and Hamartomas of the Skin 697 60. Blugerman G et al: Multiple eccrine hidrocysto- 76. Helwig EB, Hackney VC: Syringocystadenoma mas: A new therapeutic options with botulinum papilliferum. Arch Dermatol 71:361, 1955 toxin. Dermatol Surg 29:557, 2003 77. Karg E et al: Congenital syringocystadenoma pap- 61. Del Pozo J et al: Multiple apocrine hidrocystomas: illiferum. Pediatr Dermatol 25(1):132-133, 2008 Treatment with carbon dioxide laser evaporation. 78. Mammino JJ, Vidmar DA: Syringocystadenoma J Dermatol Treat 12:97, 2001 papilliferum. Int J Dermatol 30:763-766, 1991 62. Gupta S et al: The efficacy of electrosurgery and 79. Boni R et al: Syringocystadenoma papilliferum: A excision in treating patients with multiple apo- study of potential tumor suppressor genes. Am J crine hidrocystomas. Dermatol Surg 27:382, 2001 Dermatopathol 23(2):87-89, 2001 63. Tansi E, Alster TS: Pulsed dye laser treatment 80. Philipone E, Chen S: Unique case: Syringocystad- of multiple eccrine hidrocystomas: A novel ap- enoma papilliferum associated with an eccrine proach. Dermatol Surg 27:898, 2001 nevus. Am J Dermatopathol. 31(8):806-807, 2009 64. Vakilzadeh F et al: Fokale dermal hypoplaise mi 81. Schaffer JV et al: Syringocystadenoma papil- apokrinen naeivi and streifenfoermiger anomalie liferum in a patient with focal dermal hypoplasia der knochen. Arch Dermatol 256:189, 1976 due to a novel PORCN mutation. Arch Dermatol 65. Liu HM et al: Facial apocrine fibroadenoma 145(2):218-219, 2009 in man: A rare finding. Am J Dermatopathol 82. Chi CC, Tsai RY, Wang SH: Syringocystadenocarci- 29(3):274-278, 2007 noma papillferum successfully treated with Mohs 66.